carvedilol has been researched along with endothelin-1 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fyhrquist, F; Metsärinne, K; Saijonmaa, O | 1 |
| Arleth, AJ; Ohlstein, EH; Romanic, AM; Storer, B | 1 |
| Donckier, J; Godfraind, T; Heyndrickx, GR; Kyselovic, J; Massart, PE; Wibo, M | 1 |
| Iida, H; Iwasawa, K; Jo, T; Ma, J; Nagai, R; Nakajima, T; Omata, M | 1 |
| Backes, RJ; Bailey, KR; Burnett, JC; Frantz, RP; Grill, D; Hanna, RD; Heublein, D; Mookadam, F; Moualla, SK; Nelson, SM; Nobrega, TP; Olson, LJ | 1 |
| Gackowski, A; Kitliński, M; Nessler, B; Nessler, J; Piwowarska, W; Stepniewski, M | 1 |
| Gao, RL; Liu, YX; Pei, WD; Sun, YH; Yang, YJ; Zhai, M; Zhao, JL | 1 |
| Mei, Z; Xiaozhen, H; Yu, S; Yun, Z | 1 |
| Inrig, JK; Kim, C; Povsic, TJ; Toto, R; Van Buren, P; Vongpatanasin, W | 1 |
| Fedorowski, A; Gackowski, A; Golebiowska-Wiatrak, R; Kitlinski, M; Melander, O; Nessler, B; Nessler, J; Palka, I | 1 |
5 trial(s) available for carvedilol and endothelin-1
| Article | Year |
|---|---|
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Carvedilol; Endothelin-1; Endothelins; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines | 2005 |
Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Endothelin-1; Exercise; Exercise Test; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Propanolamines; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left | 2008 |
Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy.
Topics: Administration, Sublingual; Adrenergic beta-Antagonists; Aged; Blood Flow Velocity; Blood Pressure; Brachial Artery; Carbazoles; Carvedilol; Coronary Circulation; Diastole; Dipyridamole; Echocardiography, Transesophageal; Endothelin-1; Endothelium, Vascular; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Injections, Intravenous; Male; Metoprolol; Middle Aged; Nitroglycerin; Propanolamines; Vasodilation; Vasodilator Agents | 2010 |
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.
Topics: AC133 Antigen; Adult; Aged; Aldehyde Dehydrogenase; Antigens, CD; Antigens, CD34; Antihypertensive Agents; Arginine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Carbazoles; Carvedilol; Endothelin-1; Endothelium, Vascular; Female; Glycoproteins; Humans; Hypertension; Male; Middle Aged; Peptides; Pilot Projects; Propanolamines; Prospective Studies; Renal Dialysis; Stem Cells; Texas; Time Factors; Treatment Outcome; Vascular Stiffness; Vasodilation; Vasodilator Agents | 2012 |
Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; C-Reactive Protein; Carbazoles; Carvedilol; Endothelin-1; Female; Heart Failure; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Poland; Propanolamines; Stroke Volume; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2013 |
5 other study(ies) available for carvedilol and endothelin-1
| Article | Year |
|---|---|
Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Ascorbic Acid; Calcium Channel Blockers; Carbazoles; Carvedilol; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Humans; Metoprolol; Nicardipine; Prazosin; Probucol; Propanolamines; Propranolol; Umbilical Veins | 1997 |
Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells.
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Carvedilol; Cells, Cultured; Coronary Vessels; Endothelin-1; Endothelium, Vascular; Gene Expression Regulation; Humans; Propanolamines; RNA, Messenger | 1998 |
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Topics: Actins; Animals; Antihypertensive Agents; Aortic Diseases; Blood Pressure; Carbazoles; Carotid Arteries; Carvedilol; Constriction, Pathologic; Dihydropyridines; Disease Models, Animal; Endothelin-1; Endothelins; Gene Expression; Heart Rate; Heart Ventricles; Hypertrophy, Left Ventricular; Labetalol; Ligation; Male; Myocardium; Organ Size; Propanolamines; Protein Precursors; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger | 1999 |
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aorta; Calcium; Calcium Channels; Calcium Signaling; Carbazoles; Carvedilol; Cell Division; Endothelin-1; Metoprolol; Muscle, Smooth, Vascular; Nicardipine; Nifedipine; Propanolamines; Rats; Vasodilator Agents; Vasopressins | 2003 |
Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Disease Models, Animal; Endothelin-1; Glyburide; Hypoglycemic Agents; KATP Channels; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Potassium Channel Blockers; Propanolamines; Swine; Swine, Miniature | 2008 |